A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,301–2,400 of 3,967
Zhang, H.-Y., Pang, L., Lv, X., Liu, C., & Nan, M.-H. (2020) · Medicine · doi:10.1097/md.0000000000022396 · Cited by 7
Clinical Overview of Progressive Fibrotic Interstitial Lung Disease
Case, A. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.858339 · Cited by 8
“The antifibrotic drugs, nintedanib and pirfenidone, both have proven clinical benefit in IPF (60, 61), and both are being studied in non-IPF PF-ILD.”
BackgroundHermansky-Pudlak syndrome: Gene therapy for pulmonary fibrosis
Nieto-Alamilla, G., Behan, M., Hossain, M. S., Gochuico, B. R., & Malicdan, M. C. V. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.08.008 · Cited by 7
Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease
Salonen, J., Jansa, S., Vähänikkilä, H., & Kaarteenaho, R. L. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02534-0 · Cited by 8
Majewski, S., Białas, A. J., Barczyk, A., Batura‐Gabryel, H., Buchczyk, M., Doboszyńska, A., Górska, K., Grabowska-Szkudlarz, L., Jagielska-Len, H., Jarzemska, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144635 · Cited by 9
Wu, Y., Zhang, J., Wang, X., Xu, Y., & Zheng, J. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152100 · Cited by 9
Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers
Choi, B., Estépar, R. S. J., Godbole, S. V., Curtis, J. L., Wang, J. M., Estépar, R. S. J., Rosas, I. O., Mayers, J. R., Hobbs, B. D., Hersh, C. P., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02576-2 · Cited by 8
Marcoux, V. S., Lok, S. D., Mondal, P. K., Assayag, D., Fisher, J. H., Shapera, S., Morisset, J., Manganas, H., Fell, C. D., Hambly, N., et al. (2024) · Respirology · doi:10.1111/resp.14695 · Cited by 7
Wang, S., Yang, G., Zhang, K., Chen, Z., Qiu, M., Hou, S., Zheng, T., Wu, Z., Ma, Q., Zhang, F., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107474 · Cited by 7
Hozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02922-y · Cited by 10
Selcuk, Ö., & Uslu, B. (2024) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ad6a94 · Cited by 7
Glenn, L. M., Jackson, D., Barton, C., Lan, D., Fuhrmeister, L., Symons, K., Turnour, L., Tefay, B., Holland, A. E., Goh, N. S. L., et al. (2024) · Respirology · doi:10.1111/resp.14874 · Cited by 7
Self-citationPirfenidone Mitigates Transforming Growth Factor-β–induced Inflammation after Viral Infection
Thomas, B. J., Kan‐o, K., Gantier, M. P., Simpson, I., Chitty, J. G., Lam, M., Dousha, L. F., Gottschalk, T. A., Lawlor, K. E., Tate, M. D., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0433oc · Cited by 10
Mi, Z., Zhou, Y., Yang, X., Zhou, K., & Zhu, X. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1578480 · Cited by 9
Froidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7
Lung carcinogenesis and fibrosis taken together: just coincidence?
Giopanou, I., Arendt, K. A. M., & Stathopoulos, G. T. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000390 · Cited by 7
Jones, M. G., Sgalla, G., & Richeldi, L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1666ed · Cited by 7
Spek, C. A., & Duitman, J. (2018) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.2017s2.004 · Cited by 6
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 9
Caro, F. M., Alberti, M. L., Campins, F., Enghelmayer, J. I., Fernández, M. E., Lancellotti, D., Papucci, T., Sebastiani, J. A., & Paulín, F. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2018.12.007 · Cited by 7
Camuset, J., Naccache, J., Dhalluin, X., et al. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.10.618 · Cited by 7
Biomarkers and early treatment of idiopathic pulmonary fibrosis
Kropski, J. A. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30256-5 · Cited by 8
Pirfenidone ameliorates the formation of choroidal neovascularization in mice
Bao, Y., Huang, L., Huang, X., Gao, C., Chen, Y., Wu, L., Zhu, S., & Song, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11007 · Cited by 8
The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
Sarkar, P., Avram, C., & Chaudhuri, N. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1784730 · Cited by 8
Fukihara, J., Maiolo, S., Kovac, J. H., et al. (2022) · Experimental Lung Research · doi:10.1080/01902148.2021.2024301 · Cited by 7
Mikami, S., Miura, Y., Kondo, S., Sakai, K., Nishimura, H., Kyoyama, H., Moriyama, G., Koyama, N., Noguchi, H., Ohkubo, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270056 · Cited by 9
Cheng, S.-L., Sheu, C., Chian, C., Hsu, J., Kao, K., Hang, L., Lin, C., Fang, W., Wang, H., & Perng, D. (2022) · Biomedicines · doi:10.3390/biomedicines10102362 · Cited by 7
Razi, O., Teixeira, A. M., Tartibian, B., Zamani, N., & Knechtle, B. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04610-1 · Cited by 8
Zou, X., Huang, Z., Zhan, Z., Yuan, M., Zhang, Y., Liu, T., Hu, X., Fan, W., Chen, P., Qin, H., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116520 · Cited by 9
Horan, G. S. B., Ye, Y., Adams, M., Parton, A., Cedzik, D., Tang, S., Brown, E. A., Liu, L., Nissel, J., Carayannopoulos, L. N., et al. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1294 · Cited by 8
Liang, Y., Fan, S., Jiang, Y., Ji, T., Chen, R., Xu, Q., Liu, Y., Xiao, Y., Cai, H., & Dai, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110754 · Cited by 7
Luo, W., Gu, Y., Fu, S., Wang, J., Zhang, J., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115762 · Cited by 7
Huang, Y., Liu, F., Ren, S., Ding, Y., Chi, M., Huang, W., Gu, W., Qian, H., Yuan, Y., Hou, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01764 · Cited by 8
Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis
Tzilas, V., & Bouros, D. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00205914 · Cited by 9
Insights into idiopathic pulmonary fibrosis in the real world
Cottin, V., & Wuyts, W. A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00036815 · Cited by 8
Sisson, T. H., & Spagnolo, P. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2319ed · Cited by 7
Clinical Features and Treatment of Scleroderma
Wigley, F. M., & Boin, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00084-x · Cited by 15
A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure
Girgis, R. E., & Khaghani, A. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.5 · Cited by 7
Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies
Lunardi, F., Pezzuto, F., Vuljan, S. E., & Calabrese, F. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0080-ra · Cited by 6
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software
Bennett, D., Mazzei, M. A., Collins, B. F., Bargagli, E., Pipavath, S. J., Spina, D., Valentini, M. L., Rinaldi, C., Bettini, G., Ginori, A., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.011 · Cited by 7
Wright, C., Hart, S. P., Allgar, V. L., English, A., Swan, F., Dyson, J., Richardson, G. A., Twiddy, M., Cohen, J., Hussain, J. A., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00186-2019 · Cited by 8
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Kulkarni, T., & Duncan, S. R. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-00238-7 · Cited by 8
Gender equity in interstitial lung disease
Kawano-Dourado, L. B., Glassberg, M. K., Molina‐Molina, M., Strek, M. E., Wijsenbeek, M. S., & Johannson, K. A. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30310-6 · Cited by 8
Self-citationDynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis
Davidsen, J. R., Lund, L. C., Laursen, C. B., Hallas, J., & Henriksen, D. P. (2020) · ERJ Open Research · doi:10.1183/23120541.00479-2020 · Cited by 7
Eldersveld, J. M., Yi, E. S., Kunze, K. L., Smith, M. L., Tazelaar, H. D., & Larsen, B. T. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0100-oa · Cited by 7
Chang, W., Chen, C.-M., Sheu, C., Liao, S., Hsu, Y., Tsai, M., & Kuo, P. (2020) · Molecules · doi:10.3390/molecules25225458 · Cited by 10
Aronson, K. I., Ali, M., Reshetynak, E., Kaner, R. J., Martínez, F. J., Safford, M. M., & Pinheiro, L. C. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00282-x · Cited by 10
Antifibrotics in systemic sclerosis
Martín-López, M., & Carreira, P. E. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101671 · Cited by 7
Wells, A. U. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00173-9 · Cited by 7
Gao, Y., Zhong, L. L. D., Quach, B., Davies, B., Ash, G. I., Lin, Z., Feng, Y., Lau, B. W.-M., Wagner, P. D., Yang, X., et al. (2021) · JMIR Research Protocols · doi:10.2196/25556 · Cited by 7
Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease
Newton, C. A., & Herzog, E. L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.011 · Cited by 7
Bai, Y., Zhang, Y., Chu, P., Wang, C., Li, L., Qi, Y., Han, X., Zhang, B., Sun, H., Li, Y., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128238 · Cited by 9
Kang, M., Veeraraghavan, S., Martin, G. S., & Kempker, J. A. (2021) · ERJ Open Research · doi:10.1183/23120541.00142-2021 · Cited by 9
Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis
Wu, Y., Qi, Y., Qiu, Z., & Chen, W. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.013 · Cited by 8
Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada
Weatherald, J. C., McFadden, R. G., & Fell, C. D. (2017) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2017.1314778 · Cited by 8
Recommendations for evaluating and managing idiopathic pulmonary fibrosis
Provencher, D. M., & Jauregui, A. R. (2018) · JAAPA · doi:10.1097/01.jaa.0000544299.00459.a4 · Cited by 7
Xu, C., Wang, P., Lin, C. X., Luo, Z., Huang, Y., Zhao, Z., & Yang, C. (2018) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2018.11.007 · Cited by 8
Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice
Urushiyama, H., Terasaki, Y., Nagasaka, S., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14255 · Cited by 7
Outcome of lung transplantation in non‐idiopathic pulmonary fibrosis interstitial lung disease
Bode, H., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Verleden, G. M., & Vos, R. (2019) · Clinical Transplantation · doi:10.1111/ctr.13661 · Cited by 8
Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction
Harari, S. A., Specchia, C., Lipsi, R., Cassandro, R., & Caminati, A. (2020) · Respiration · doi:10.1159/000508667 · Cited by 8
Combined Pulmonary Fibrosis and Emphysema, a clinical review
Tzilas, V., & Bouros, D. E. (2016) · COPD Research and Practice · doi:10.1186/s40749-016-0018-1 · Cited by 7
“Currently, there are two approved drugs for the treatment of IPF, pirfenidone [44, 45] and nintedanib [46].”
BackgroundShih, C. T., Yang, M., Lai, S. T., & Lin, C. (1994) · PubMed · Cited by 7
Ziehr, D. R., Li, F., Parnell, K. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.25.591150 · Cited by 7
Song, L., Zhou, H., Ye, P., Li, Q., Chen, K., Zhang, Y., Zhao, F., Shi, J., Luo, Y., Zhu, M., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13654 · Cited by 6
Cheung, D., Fong, A., Ding, H. T., Cabanski, C. R., Wang, J., Chen, Y., Bush, J., Harris, J. M., & Pan, L. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102051 · Cited by 6
The interstitial lung disease patient pathway: from referral to diagnosis
Lough, G., Abdulqawi, R., Amanda, G., Antoniou, K., Azuma, A., Baldi, M. M., Bayoumy, A., Behr, J., Bendstrup, E. M., Bouros, D. E., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00899-2024 · Cited by 7
Self-citationQiu, Y., Zhu, J., Chopra, P., Elpers, B., Dieyi, C., Byrne, C., Tang, J., Ye, W., Govindaraj, K., & Fischer, A. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241280704 · Cited by 7
Miranda, S. M. D., Paiva, S. D. P. C., Pereira, L. F. F., et al. (2024) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2024.103106 · Cited by 6
Identification of a Potent CDK8 Inhibitor Using Structure-Based Virtual Screening
Lin, T. E., Chou, C.-H., Wu, Y., Sung, T.-Y., Hsu, J., Yen, S., Hsieh, J., Chang, Y.-W., Pan, S., Huang, W., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02011 · Cited by 6
Cocconcelli, E., Bernardinello, N., Cameli, P., Liberti, R., Alhamad, E. H., Gregori, D., Pianigiani, T., Dartora, C., Messina, R., Leo, I. D., et al. (2025) · Lung · doi:10.1007/s00408-025-00789-4 · Cited by 11
Deng, B., Su, P. J., Lu, C. Y., Zhang, J., Zhang, X., Yu, T., Bao, G., Yan, T., Yin, Y. H., Shen, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00133 · Cited by 7
Zhang, C., Wang, Y., Cui, X., Zhang, Q., Cong, H., Liu, J., Ren, J., & Tang, J. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2497369 · Cited by 7
Wang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., Zhou, L., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530697 · Cited by 17
Treatable traits in interstitial lung disease: a narrative review
Harrison, M., Lawler, C., Lake, F., Navaratnam, V. V., Fermoyle, C. C., Moodley, Y. P., & Corte, T. J. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335774 · Cited by 8
Takuma, S., Hozumi, H., Miyashita, K., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108185 · Cited by 6
Sharifi, H., Moss, C. T., Musa, Z., Bell, A., O’Donnell, C. T., Borges, C. H., Matthaiou, E. I., Johnston, L., Galbán, C. J., Sheshadri, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016122 · Cited by 8
Alamandine reduces oxidative stress and preserves the epithelium in BLM-induced pulmonary fibrosis
Blanco, A., Fernandes, R., Guimarães, G. R., & Rigatto, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177995 · Cited by 6
Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects
Ahmed, K. A., Afrin, N., Ghosh, P., Heya, I. A., Akash, S. R., Moni, A., Islam, M. N., Hossain, M. G., Sinopoli, A., Hannan, M. A., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70163 · Cited by 7
Lalla, F., Latella, A., Varone, F., Iovene, B., Richeldi, L., & Sgalla, G. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03916-2 · Cited by 12
Assayag, D., Adegunsoye, A., Khor, Y. H., Bonella, F., Borie, R., Buendía-Roldán, I., Chaudhuri, N., Gibson, K. F., Johannson, K. A., Kaminski, N., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202509-2336st · Cited by 7
Ohmoto, A., Fuji, S., Kohmo, S., & Katsura, K. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2151437 · Cited by 5
Wang, P., Li, H., Chen, S., Xing, H., Yang, J., Zhang, G., & Zhang, X. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01250-6 · Cited by 6
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
Ford, P., Kreuter, M., Brown, K. K., Wuyts, W. A., Wijsenbeek, M. S., Israël‐Biet, D., Hubbard, R., Nathan, S. D., Nunès, H., Penninckx, B., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00636-2023 · Cited by 10
Self-citationPhillips, A. E., Hughes, S. J., Andersen, D. K., Bell, A., Brand, R. E., Coté, G. A., Cowdin, A., Diazgranados, N., Dudeja, V., Duggan, S. N., et al. (2024) · Pancreas · doi:10.1097/mpa.0000000000002333 · Cited by 8
Wang, H., Tsai, S., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02947-5 · Cited by 9
Wang, Y., Xue, F., Cheng, W., Zhao, Q., Song, N., Shi, Z., Liu, H., Li, Y., Tang, Q., Liu, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00067 · Cited by 6
Pulmonary Manifestations of Sjögren's Disease
Byrne, L., McCarthy, C., Fabre, A., & Gupta, N. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1785675 · Cited by 9
When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis
Zamora, A., Ortega, V. E., & Carmona, E. M. (2024) · JAMA · doi:10.1001/jama.2024.8776 · Cited by 7
Adiponectin suppresses stiffness-dependent, profibrotic activation of lung fibroblasts
Németh, J., Skrońska-Wąsek, W., Keppler, S., Schundner, A., Groß, A., Schönberger, T., Quast, K., Kasmi, K. C. E., Ruppert, C., Guenther, A., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2024 · Cited by 9
The Impact of Nintedanib Dosing on Clinical Outcomes
LIMPER, A. H., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & Dempsey, T. M. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.09.030 · Cited by 6
Tondo, P., Scioscia, G., Pace, C. C. D., Murgolo, F., Maci, F., Stella, G. M., Pescatore, D., Barbaro, M. P. F., & Lacedonia, D. (2025) · Life · doi:10.3390/life15010106 · Cited by 8
Quan, J., Ma, C., Zhao, X., Guo, Y., Qu, W., Zhou, X., Ma, E., & Xu, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108360 · Cited by 6
Paone, G., Sebastiani, A., Ialleni, E., Diso, D., Rose, D., Quagliarini, F., Ialongo, P., Peruzzi, M., Venuta, F., & Frati, G. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.02.006 · Cited by 5
Effect of pirfenidone on gastric emptying in a rat model
Pan, L., Gelzleichter, T. R., Chen, Y., Burg, C., Limb, S. L., & Nguyen, L. A. B. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.06.001 · Cited by 7
Sadon, A. A.-A., Kenawy, A. S., Abdelsalam, A., & Attia, H. (2020) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ejcdt.ejcdt_140_19 · Cited by 6
Zheng, X.-F., Xie, B., Liu, Y., Zhu, M., Zhang, S., Ban, C., Geng, J., Jiang, D., Ren, Y., Dai, H., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001089 · Cited by 6
Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?
Tang, H., Ren, Y., She, Y., Dai, C., Wang, T., Su, H., Sun, W., Jiang, G., & Chen, C. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620971137 · Cited by 7
Kirsten, D. K., de Vries, U., Costabel, U., Koschel, D., Bonella, F., Günther, A., Behr, J., Claussen, M., Schwarz, S., Prasse, A., et al. (2021) · Pneumologie · doi:10.1055/a-1579-7618 · Cited by 7
Three-Dimensional Idiopathic Pulmonary Fibrosis Model Using a Layer-by-Layer Cell Coating Technique
Kuno, H., Akagi, T., Fukui, E., Yamato, H., Akashi, M., & Shintani, Y. (2021) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2020.0365 · Cited by 6
Dorey-Stein, Z. L., Shapiro, W., Zhao, H., CORDOVA, F. C., Criner, G. J., & Galli, J. A. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106599 · Cited by 7
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.